Newly-floated biotech links up with Oxford

A BIOTECH company pioneering blood cancer treatments is to unveil a tie-up with Oxford University this week, a month after listing on the London Stock Exchange.

Hemogenyx is developing antibodies to treat leukaemia and lymphoma that it hopes will eliminate the need for chemotherapy and radiotherapy.

These treatments will target only affected cells, meaning more patients will be able to undergo bone marrow transplants, required in recurring cases of blood diseases. The link-up with Oxford will test if the process makes blood cells healthy.

Hemogenyx chief Dr Vladislav Sandler said the link-up could ‘completely transform’ the treatment of blood cancers. Shareholders of Hemogenyx include ‘Ivy League’ Cornell University, in New York State, where Sandler developed the pioneering technology.

The £10million start-up is headquartered in London but its labs are in New York.